In immunocompetent breast cancer models, Axl deletion resulted in increased CD8+ T-cell infiltration and tumor regression only when combined with PD-1 inhibition, leading to improved survival compared to either treatment alone. This evidence concerns the gene AXL and breast carcinoma.